Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDrreddyslaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Prefer Alembic Pharma: Mehraboon Irani

      Mehraboon Irani of Nirmal Bang Securities is of the view that one may prefer Alembic Pharmaceuticals from the pharma space.

    • Positive on largecap pharma stocks, cement: Deven Choksey

      Deven Choksey of KRChoksey Investment Managers has a positive view on largecap pharma stocks and the cement space.

    • Buy Dr Reddy's Labs, Infosys: Rajat Bose

      Rajat Bose of rajatkbose.com recommends buying Dr Reddy's Laboratories and Infosys.

    • Cipla top bet from pharma space, says Jai Bala

      Jai Bala of Cashthechaos.com is of the view that Cipla is the top bet from the pharma space.

    • Buy Dr Reddy's, Cairn India, Reliance Industries: Rajat Bose

      Rajat Bose of rajatkbose.com recommends buying Dr Reddy's Laboratories, Cairn India and Reliance Industries.

    • Buy Sun Pharma 840 Call, Dr Reddy's Labs 3100 Call: VK Sharma

      VK Sharma of HDFC Securities is of the view that one can buy Sun Pharma 840 Call and Dr Reddy's Labs 3100 Call.

    • Super Six: Top chart picks for January 28

      Gaurav Bissa of LKP Securities advises selling Maruti Suzuki with a target of Rs 4000.

    • Buy HDFC Bank, Dr Reddy's Labs may hit Rs 2970: Rajat Bose

      Rajat Bose of rajatkbose.com recommends buying HDFC Bank and feels that Dr Reddy's Labs may test Rs 2970.

    • Hold Alembic Pharma, may test Rs 750-800: Vijay Chopra

      Vijay Chopra of enochventures.com is of the view that one may hold Alembic Pharmaceuticals with a target of Rs 750-800.

    • Buy Glenmark Pharma; like Lupin, Dr Reddy's Lab: Abhishek Sharma

      Abhishek Sharma, Pharma Analyst at IIFL recommends buying Glenmark Pharma and likes Lupin and Dr Reddy's Labs.

    • Short Dr Reddy's Laboratories, target Rs 2700: Shubham Agarwal

      Shubham Agarwal of Motilal Oswal Securities recommends shorting Dr Reddy's Laboratories for a target of Rs 2700.

    • Sell Dabur India, Adani Ports: Rajat Bose

      Rajat Bose of rajatkbose.com recommends selling Dabur India and Adani Ports.

    • 6 stocks likely to see lot of action today

      Hemen Kapadia of KRChoksey Securities advises buying Hindustan Unilever with a target of Rs 822.

    • Dr Reddy's Lab may test Rs 4300, says Rajat Bose

      Rajat Bose of rajatkbose.com feels that Dr Reddy's Laboratories may test Rs 4300 and Nelco may test Rs 129.

    • Buy IndusInd Bank; sell BPCL: Prakash Gaba

      Prakash Gaba of prakashgaba.com advises buying IndusInd Bank and suggests selling Bharat Petroleum Corporation.

    • Eveready Industries may move to Rs 360: Rajat Bose

      Rajat Bose of rajatkbose.com feels that Eveready Industries may move to Rs 360.

    • Look at Aurobindo Pharma, Dr Reddy's Lab: Dilip Bhat

      According to Dilip Bhat of Prabhudas Lilladher, one may look at Aurobindo Pharma and Dr Reddy's Laboratories.

    • Pick Bharat Forge, HDFC Bank, Dr Reddy's Lab: Prakash Gaba

      Prakash Gaba of prakashgaba.com is of the view that one may pick Bharat Forge, HDFC Bank and Dr Reddy's Laboratories.

    • Invest in Aurobindo Pharma, Lupin, Divis Lab: Sukhani

      According to Sudarshan Sukhani of s2analytics.com, Aurobindo Pharma, Lupin and Divis Laboratories are investment ideas.

    • Go long in Dr Reddy's Laboratories: Siddarth Bhamre

      Siddarth Bhamre of Angel Broking is of the view that one may go long in Dr Reddy's Laboratories.

    • Dr Reddy's Labs: The bull vs bear case

      Shares of Dr Reddy's Labs have been on a downward journey over the past two months, amid concerns over a warning letter the company received from the US FDA over some of its plants, and amid some currency headwinds it faces.

    • Short Idea, Glenmark; buy Colgate: Prakash Gaba

      Watch the interview of Prakash Gaba of prakashgaba.com with Latha Venkatesh & Sonia Shenoy on CNBC-TV18, in which he shared his readings and outlook on the market, specific stocks and sectors.

    • Avoid Dr Reddy's Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can avoid Dr Reddy's Laboratories.

    • Prefer Lupin: Sudip Bandopadhyay

      Sudip Bandopadhyay, Market Expert is of the view that one may prefer Lupin from the pharma space.

    • Buy Dr Reddy's Lab, may test Rs 3600-3800: Simi Bhaumik

      Simi Bhaumik of simibhaumik.com is of the view that one may buy Dr Reddy's Laboratories as the stock may test Rs 3600-3800.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347